跳转至内容
Merck
CN

F3254

Fibrinopeptide A 人

≥96% (HPLC)

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C63H97N19O26
化学文摘社编号:
25422-31-5
分子量:
1536.56
NACRES:
NA.77
PubChem Substance ID:
24894837
UNSPSC Code:
12352202
MDL number:
MFCD00076437
Form:
powder
Assay:
≥96% (HPLC)
Biological source:
human

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

JWICNZAGYSIBAR-UHFFFAOYSA-N

SMILES string

CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(O)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(CO)NC(=O)C(CC(O)=O)NC(=O)C(C)N)C(=O)NC(C)C(=O)NC(CCC(O)=O)C(=O)NCC(=O)NCC(=O)NCC(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(O)=O

InChI

1S/C63H97N19O26/c1-29(2)19-37(57(102)73-32(6)53(98)76-35(15-17-48(91)92)55(100)70-24-43(85)68-23-42(84)69-25-46(88)82-51(30(3)4)61(106)77-36(62(107)108)13-10-18-67-63(65)66)79-58(103)38(20-33-11-8-7-9-12-33)80-59(104)39(21-49(93)94)75-45(87)27-71-54(99)34(14-16-47(89)90)74-44(86)26-72-56(101)41(28-83)81-60(105)40(22-50(95)96)78-52(97)31(5)64/h7-9,11-12,29-32,34-41,51,83H,10,13-28,64H2,1-6H3,(H,68,85)(H,69,84)(H,70,100)(H,71,99)(H,72,101)(H,73,102)(H,74,86)(H,75,87)(H,76,98)(H,77,106)(H,78,97)(H,79,103)(H,80,104)(H,81,105)(H,82,88)(H,89,90)(H,91,92)(H,93,94)(H,95,96)(H,107,108)(H4,65,66,67)

biological source

human

assay

≥96% (HPLC)

form

powder

technique(s)

ELISA: suitable, mass spectrometry (MS): suitable

UniProt accession no.

P02671

storage temp.

−20°C

Quality Level

200

Gene Information

human ... FGA(2243)

正在寻找类似产品? 访问 产品对比指南

General description

Fibrinopeptide A (FPA) is produced from the N-terminal Aα region of fibrinogen protein, on cleavage by thrombin. It is composed of 16 amino acids.

Application

Fibrin polymerization is initiated by thrombin cleavage of fibrinopeptide A from fibrinogen α chains, exposing two E domain E(A) sites.

Biochem/physiol Actions

Fibrin polymerization is initiated by thrombin cleavage of fibrinopeptide A from fibrinogen α chains, exposing two E domain E(A) sites. The phenylalanine at α chain residue 8 is important for efficient thrombin-catalyzed proteolysis of fibrinogen. Substitution of tyrosine for phenylalanine blocks sequential fibrinopeptide release and, thus, blocks polymerization and clot formation.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000395659
0000316864
0000295503
0000316864
0000395659

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Xi Chen et al.
Environmental toxicology and pharmacology, 33(2), 191-196 (2012-01-10)
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitously distributed endocrine disruptors. To investigate peptide changes in the sera of rats chronically exposed to TCDD and to explore the association of these changes with liver morphology, TCDD was administrated to male rats at doses
Laura A Da Costa et al.
The Journal of nutritional biochemistry, 24(1), 396-400 (2012-12-04)
Vitamin E is a lipophilic antioxidant that has been inversely associated with certain chronic diseases; however, the biological processes regulated by this vitamin have not been fully elucidated. The objective of the present study was to examine the association between
H L Nossel et al.
The Journal of clinical investigation, 54(1), 43-53 (1974-07-01)
Since thrombin cleaves fibrinopeptides A (FPA) and B from the NH(2)-terminal end of the fibrinogen molecule, measurement of fibrinopeptide levels in plasma may provide a direct index of thrombin action. Recently a radioimmunoassay for FPA has been developed, and in
Routine heparin for patients with cancer? One answer, more questions.
Elie A Akl et al.
The New England journal of medicine, 366(7), 661-662 (2012-02-18)
Giancarlo Agnelli et al.
The New England journal of medicine, 366(7), 601-609 (2012-02-18)
Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism. Limited data support the clinical benefit of antithrombotic prophylaxis. In this double-blind, multicenter trial, we evaluated the efficacy and safety of the ultra-low-molecular-weight heparin semuloparin for prevention of
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持